RGD Reference Report - miRNA-30a functions as a tumor suppressor by downregulating cyclin E2 expression in castration-resistant prostate cancer. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

miRNA-30a functions as a tumor suppressor by downregulating cyclin E2 expression in castration-resistant prostate cancer.

Authors: Zhang, Lei  Zhang, Xiao-Wen  Liu, Chun-Hui  Lu, Kai  Huang, Ye-Qing  Wang, Yi-Duo  Xing, Li  Zhang, Li-Jie  Liu, Ning  Jiang, Hua  Sun, Chao  Yang, Yu  Chen, Shu-Qiu  Chen, Ming  Xu, Bin 
Citation: Zhang L, etal., Mol Med Rep. 2016 Sep;14(3):2077-84. doi: 10.3892/mmr.2016.5469. Epub 2016 Jul 6.
RGD ID: 13504681
Pubmed: PMID:27431942   (View Abstract at PubMed)
DOI: DOI:10.3892/mmr.2016.5469   (Journal Full-text)

MicroRNAs (miRNAs) act as tumor promoters or tumor suppressors in different human malignancies. In the current study, using an Agilent miRNA microarray, miR-30a was found to be a significantly downregulated miRNA in castration-resistant prostate cancer (CRPC) tissues, compared with androgen-dependent prostate cancer tissues. Aberrant expression of cyclin E2 (CCNE2) has been reported in a variety of types of cancer including prostate cancer, and correlates with clinical outcome. The purpose of the current study was to determine the functions of miR-30a in CRPC cell lines and identify whether CCNE2 was regulated by miR-30a. To analyze the associations between miR-30a and CCNE2 expression levels, pathological specimens were collected, and reverse transcription-quantitative polymerase chain reaction and immunohistochemical staining were conducted. The effect of miR-30a overexpression on CRPC cell lines and the predicted target gene, CCNE2, were evaluated by MTT assay, flow cytometry, tumor formation, luciferase reporter assay and western blotting. miR-30a overexpression resulted in a significant suppression of cell growth in vitro, and reduced tumorigenicity in vivo. miR-30a repressed the expression of CCNE2 through binding to its 3'-untranslated region. CCNE2 was observed to be overexpressed in patients with CRCP and had an approximately inverse correlation with the level of miR-30a. The results suggest that miR-30a may function as a novel tumor suppressor in CRPC. Its anti-oncogenic activity may occur by the reduced expression of a distinct cell cycle protein, CCNE2.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
CCNE2Humancastration-resistant prostate carcinoma treatmentIDA  RGD 
Ccne2Ratcastration-resistant prostate carcinoma treatmentISOCCNE2 (Homo sapiens) RGD 
Ccne2Mousecastration-resistant prostate carcinoma treatmentISOCCNE2 (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ccne2  (cyclin E2)

Genes (Mus musculus)
Ccne2  (cyclin E2)

Genes (Homo sapiens)
CCNE2  (cyclin E2)

Objects referenced in this article
Gene ATF4 activating transcription factor 4 Homo sapiens
Gene Atf4 activating transcription factor 4 Mus musculus
Gene Atf4 activating transcription factor 4 Rattus norvegicus

Additional Information